Abstract:

As a common vector transfection tool, lentivirus has become the first choice for gene therapy of ophthalmic diseases because of its advantages of high efficiency, large transgene, and stable integration in host cells, such as ocular neovascular diseases  applied to animal models, and retinal hereditary diseases, glaucoma, etc., have made some progress in research but have not been used clinically. The application of lentivirus focused on the ocular diseases such as Stargardt disease, diabetic retinopathy and corneal transplantation to lay the foundation for the study of the treatment of ophthalmic diseases through the regulation of gene expression.